Research programme: insulin oral - Abeona Therapeutics

Drug Profile

Research programme: insulin oral - Abeona Therapeutics

Alternative Names: cobalamin-coated insulin-containing nanoparticles; CobOral™ Insulin

Latest Information Update: 11 Aug 2015

Price : $50

At a glance

  • Originator Access Pharmaceuticals
  • Developer Abeona Therapeutics
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Diabetes mellitus

Most Recent Events

  • 10 Feb 2014 This programme is still in preclinical development in USA
  • 10 Feb 2014 Research programme: insulin oral - Access Pharmaceuticals is available for licensing as of 20 Mar 2013. http://www.accesspharma.com
  • 10 Dec 2010 Access Pharmaceuticals enters into an agreement with an undisclosed major global pharmaceutical company to assess its proprietary oral insulin formulation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top